Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Eli Lilly exercises rights to Transition Therapeutics' TT-401

June 18, 2013

MannKind completes phase III study of Afrezza in type 2 diabetes

June 18, 2013

Dainippon Sumitomo Pharma presents novel selective 11-beta-HSD1 inhibitor

June 18, 2013

NGM Biopharmaceuticals and MedImmune partner to develop therapies for diabetes and obesity

June 17, 2013

Chinese team patents novel BMP-2 inhibitors

June 17, 2013

FDA accepts TherapeuticsMD IND for TX12-004HR

June 17, 2013

Japanese researchers divulge new dimer peptides for diabetes

June 17, 2013

New international collaboration to develop GPBA receptor agonists for type 2 diabetes

June 12, 2013

Merck & Co. discloses novel GPR119 receptor agonists

June 10, 2013

Eisai launches Belviq for chronic weight management

June 10, 2013

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...